Last $8.70 USD
Change Today -0.11 / -1.25%
Volume 537.6K
AFFX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 08/27/14 All times are local (Market data is delayed by at least 15 minutes).

affymetrix inc (AFFX) Key Developments

Affymetrix Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Raises Financial Guidance for the Full Year of 2014

Affymetrix Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported total revenue of $85,432,000 against $79,464,000 a year ago. Loss from operations was $304,000 against $2,951,000 a year ago. Loss before income taxes was $509,000 against $5,586,000 a year ago. Net loss was $911,000 or $0.01 basic and diluted per share against $6,107,000 or $0.09 basic and diluted per share a year ago. Non-GAAP net income was $5,157,000 or $0.07 basic and diluted per share against $2,786,000 or $0.04 basic and diluted per share a year ago. EBITDAO was $13,864,000 against $13,648,000 a year ago. Total second quarter revenue increased by $6 million or approximately 7.5%, primarily due to strength in the Genetic Analysis business unit. The capital expenditure during the second quarter was approximately $1.9 million. For the six months, the company reported total revenue of $168,403,000 against $157,409,000 a year ago. Loss from operations was $9,045,000 against $15,157,000 a year ago. Loss before income taxes was $10,711,000 against $20,347,000 a year ago. Net loss was $11,385,000 or $0.16 basic and diluted per share against $21,543,000 or $0.30 basic and diluted per share a year ago. Non-GAAP net income was $7,061,000 or $0.10 basic and diluted per share against $1,931,000 or $0.03 basic and diluted per share a year ago. EBITDAO was $26,780,000 against $24,296,000 a year ago. Based on the year-to-date performance and improved visibility in the balance of the year, the company is raising its full year guidance to total revenue of $340 million and EBITDA in the range of 14% to 15%.

Affymetrix Inc. to Report Q2, 2014 Results on Jul 31, 2014

Affymetrix Inc. announced that they will report Q2, 2014 results at 5:00 PM, Eastern Standard Time on Jul 31, 2014

Affymetrix Inc., Q2 2014 Earnings Call, Jul 31, 2014

Affymetrix Inc., Q2 2014 Earnings Call, Jul 31, 2014

Affymetrix Inc. and BioDiscovery, Inc. Launches New Analysis Software, Nexus Copy Number

Affymetrix and BioDiscovery, Inc. announced the launch of a new analysis software, Nexus Copy Number for Affymetrix, which is specifically for data generated by Affymetrix' genetic analysis platforms in cancer research, including CytoScan(R) Cytogenetics Suite and OncoScan(R) FFPE Assay Kit. CytoScan Cytogenetics Suite and OncoScan FFPE Assay Kit are key parts of Affymetrix cancer portfolio. Researchers have been finding CNVs and copy neutral changes in liquid and solid tumor samples. With the use of Nexus Copy Number, an advanced discovery tool for interrogating large data sets, researchers have been able to identify biomarkers that drive disease progression. The new Nexus Copy Number for Affymetrix software offers researchers a version of the Nexus Copy Number software that is easier to access and has been specifically tailored for Affymetrix' assays.

Affymetrix Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-05-2014 11:00 AM

Affymetrix Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-05-2014 11:00 AM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Franklin R. Witney, Chief Executive Officer, President and Director, Gavin H. J. Wood, Chief Financial Officer, Principal Accounting Officer and Executive Vice President.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AFFX:US $8.70 USD -0.11

AFFX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abcam PLC 424.25 GBp 0.00
Enzo Biochem Inc $5.78 USD -0.12
Fluidigm Corp $26.79 USD -0.15
Luminex Corp $18.71 USD -0.41
Pacific Biosciences of California Inc $5.38 USD +0.04
View Industry Companies
 

Industry Analysis

AFFX

Industry Average

Valuation AFFX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.9x
Price/Book 2.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AFFYMETRIX INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.